---
search:
  boost: 3
---

# NSAIDs

This is a subcategory of Ophthalmic Agents.

## Decision Tree

- [NSAIDS - Non-Preferred Criteria - Acuvail, Bromfenac, Bromsite, Ilevro, Nevanac, Prolensa](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?origin=OfficeDotCom&lang=en-US&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQVZUMTlJVllURFZNNFZVWkhUVjhJOTdHMiQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred    | Generic Name | Quantity | Time (Days) |
| :----------- | :----------- | :------: | :---------: |
| Diclofenac   |              |          |             |
| Flurbiprofen |              |          |             |
| Ketorolac    |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Acuvail       |              |          |             |
| Bromfenac     |              |          |             |
| Bromsite      |              |          |             |
| Ilevro        |              |          |             |
| Nevanac       |              |          |             |
| Prolensa      |              |          |             |

## Authorizations

**Length of Authorizations**: 30 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria 

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **3 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=89){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=29){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
